SBI Securities Co. Ltd. Invests $153,000 in Glaukos Co. (NYSE:GKOS)

SBI Securities Co. Ltd. acquired a new position in shares of Glaukos Co. (NYSE:GKOS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,018 shares of the medical instruments supplier’s stock, valued at approximately $153,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its position in shares of Glaukos by 275.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 807 shares in the last quarter. Williamson Legacy Group LLC acquired a new stake in shares of Glaukos in the 4th quarter worth about $868,000. US Bancorp DE raised its holdings in shares of Glaukos by 8.3% in the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier’s stock worth $914,000 after acquiring an additional 470 shares during the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of Glaukos by 1.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after acquiring an additional 89 shares during the last quarter. Finally, Versor Investments LP raised its holdings in shares of Glaukos by 55.3% in the 4th quarter. Versor Investments LP now owns 5,442 shares of the medical instruments supplier’s stock worth $816,000 after acquiring an additional 1,938 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

GKOS has been the topic of a number of analyst reports. Piper Sandler restated an “overweight” rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Stifel Nicolaus upped their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. Finally, UBS Group began coverage on shares of Glaukos in a report on Friday, December 6th. They issued a “buy” rating and a $182.00 target price on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $163.25.

Insider Activity

In related news, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,744 shares of company stock valued at $2,792,151 in the last three months. Company insiders own 6.40% of the company’s stock.

Glaukos Stock Up 0.9 %

Glaukos stock opened at $104.14 on Friday. Glaukos Co. has a twelve month low of $84.08 and a twelve month high of $163.71. The firm has a 50 day moving average price of $146.88 and a 200-day moving average price of $138.89. The company has a market capitalization of $5.89 billion, a P/E ratio of -36.29 and a beta of 1.04. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. As a group, equities analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.